Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 277 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (Part A, B, C) Clear all
Recruiting Phase 3 Interventional

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

NCT07220785
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Mibavademab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG22515 in Healthy Adults

NCT05136053
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG22515, Placebo, Immune System Activator
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977
View directory record Official record
Conditions
Obesity and Overweight
Interventions
MET233, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

NCT02341638
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Placebo, Aspirin, Itraconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cypress, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants

NCT07566130
View directory record Official record
Conditions
Healthy Volunteers
Interventions
nacresertib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Phase 1 Interventional

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-0151, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Anniston, Alabama • La Jolla, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3561774 in Participants With Dyslipidemia

NCT04644809
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
5
States / cities
Cypress, California • Long Beach, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 28, 2026, 6:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3154885 in Healthy Participants

NCT04014361
View directory record Official record
Conditions
Healthy
Interventions
LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 28, 2026, 6:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

NCT03631199
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

NCT07283263
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-985521, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 28, 2026, 6:48 PM EDT